{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:39:53Z","timestamp":1791164393836,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.ygyno.2013.09.032","type":"journal-article","created":{"date-parts":[[2013,10,4]],"date-time":"2013-10-04T07:54:12Z","timestamp":1380873252000},"page":"535-540","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer"],"prefix":"10.1016","volume":"131","clinical-trial-number":[{"clinical-trial-number":"nct00868192","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Andrea R.","family":"Hagemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiva P.","family":"Novetsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Zighelboim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Stewart","family":"Massad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Premal H.","family":"Thaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Mutch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2013.09.032_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2013.09.032_bb0010","article-title":"Cancer facts & figures","author":"AC Society","year":"2013"},{"issue":"33","key":"10.1016\/j.ygyno.2013.09.032_bb0015","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ygyno.2013.09.032_bb0020","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ygyno.2013.09.032_bb0025","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ygyno.2013.09.032_bb0030","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.09.032_bb0035","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.18_suppl.lba5002","article-title":"AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)","volume":"30","author":"Pujade-Lauraine","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ygyno.2013.09.032_bb0040","first-page":"1116","article-title":"LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes","volume":"57","author":"Shih","year":"1997","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ygyno.2013.09.032_bb0045","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ygyno.2013.09.032_bb0050","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1200\/JCO.2008.19.2963","article-title":"Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group","volume":"27","author":"Miller","year":"2009","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.ygyno.2013.09.032_bb0055","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.1200\/JCO.2008.17.0282","article-title":"Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer","volume":"26","author":"Matulonis","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2013.09.032_bb0060","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ygyno.2011.09.007","article-title":"A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer","volume":"124","author":"Sehouli","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2013.09.032_bb0065","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/1078-0432.CCR-05-1834","article-title":"Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer","volume":"12","author":"Sweeney","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ygyno.2013.09.032_bb0070","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s002800050992","article-title":"A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21days, utilizing the modified continual reassessment method for dose escalation","volume":"44","author":"Rinaldi","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.ygyno.2013.09.032_bb0075","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2013.09.032_bb0080","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2013.09.032_bb0085","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","article-title":"Acute leukemia incidence and patient survival among children and adults in the United States, 2001\u20132007","volume":"119","author":"Dores","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ygyno.2013.09.032_bb0090","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ygyno.2011.07.097","article-title":"Therapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: an epidemiological analysis","volume":"123","author":"Vay","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ygyno.2013.09.032_bb0095","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1053\/j.seminoncol.2008.04.012","article-title":"Therapy-related myeloid leukemia","volume":"35","author":"Godley","year":"2008","journal-title":"Semin Oncol"},{"issue":"33","key":"10.1016\/j.ygyno.2013.09.032_bb0100","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2013.09.032_bb0105","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ygyno.2013.09.032_bb0110","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1002\/cncr.25967","article-title":"Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study","volume":"117","author":"McGonigle","year":"2011","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2013.09.032_bb0115","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ygyno.2012.05.028","article-title":"A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer","volume":"126","author":"del Carmen","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"9375","key":"10.1016\/j.ygyno.2013.09.032_bb0120","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"issue":"29","key":"10.1016\/j.ygyno.2013.09.032_bb0125","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ygyno.2013.09.032_bb0130","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1200\/JCO.2010.32.1075","article-title":"At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis","volume":"29","author":"Cohn","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813012067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813012067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T01:13:40Z","timestamp":1564362820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825813012067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0090825813012067"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.09.032","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.09.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}